Sara Moss to Retire From the Estée Lauder Companies
25.4.2023 16:05:00 EEST | Business Wire | Press release
Today, The Estée Lauder Companies Inc. (NYSE:EL)("ELC") announced that Sara Moss, Vice Chairman, The Estee Lauder Companies, has made the decision to retire, effective July 1, 2023.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230425005169/en/
Sara Moss to retire from The Estée Lauder Companies
Sara’s outstanding career with The Estée Lauder Companies began in 2003 when she joined the organization as Executive Vice President and General Counsel, a position she served in until 2019 when she was promoted to Vice Chairman. A recognized thought leader, collaborative partner, and keen legal and business strategist, Sara served as a trusted advisor to the business, the Board of Directors and the Lauder Family throughout her tenure.
“Sara is an exceptional legal mind, a skilled advisor, a valued mentor, and a much-loved leader whose strategic insights, business acumen and sound judgment have contributed greatly to our company’s success,” said Fabrizio Freda, President and Chief Executive Officer. “Her incredible character, steadfast integrity and deep empathy will be greatly missed across the organization.”
As General Counsel, Sara led the Global Legal function, as well as the Corporate Security function, during a period of enormous growth in the business and operations of ELC. She prioritized business acumen and dedicated lawyers to each brand, region and function to support the growth and protection of the enterprise with local relevance. Notably, she oversaw the function’s initial international expansion into Europe, Asia, the Middle East, and Latin America, and collaborated closely with senior management and teams across the enterprise to execute many business-driving acquisitions, investments, and licenses of global luxury and prestige brands.
Sara has been a true champion of the company’s initiatives in Inclusion, Diversity and Equity and philanthropy. She was an inaugural member of the Diversity Council and the first Executive Sponsor of the Hispanic Connection Employee Resource Group. In 2019, she joined Jane Hertzmark Hudis, Executive Group Brand President, and Tracey T. Travis, Executive Vice President and Chief Financial Officer, as Co-Executive Sponsor of the Women’s Leadership Network (WLN). She has been a Board member of the ELC Charitable Foundation since its inception.
Upon her promotion to Vice Chairman in 2019, Sara served as a senior advisor to Executive Management, the Board of Directors, and the Lauder Family, working on a wide range of matters to strategically support the company’s long-term sustainable success.
“A trusted senior business advisor for many years, Sara has nurtured strong relationships within our global ELC family and across the wider industry,” said William P. Lauder, Executive Chairman. “It is with great appreciation, admiration, and respect that I say her dynamic leadership and expert guidance will be truly missed.”
A passionate proponent of women’s advancement, Sara partnered closely with senior leaders across the organization to drive the company’s first Women’s Advancement and Gender Equality Strategy in 2019. She demonstrated her deep commitment to supporting and engaging women to reach their full potential as leaders by creating the Open Doors Women’s Leadership Program in 2020, to help develop leadership skills, create community, and build confidence and courage among aspiring leaders across the business. In 2022, the Open Doors Collection was launched to bring these leadership skills and experiential approach to ELC employees of all genders around the world.
For the past three years, Sara also led the Social Impact pillar of the company’s integrated ESG strategy, including Women’s Advancement and Gender Equality, Racial Equity, Generational Diversity and Social Impact in China.
Sara’s impact extends far beyond the walls of ELC. In 2017 she established the Sara Moss Women’s Leadership Program at New York University Law School – her alma mater – where she also serves as a Law School Trustee and member of the Board of Directors. She is Vice Chairman of the Board of The New York Common Pantry, where she was recognized with the Distinguished Partner Award in 2020. Additionally, she serves on the Advisory Boards of the International Rescue Committee (IRC) and The Legal Aid Society. Sara has received many well-deserved honors in recognition of her outstanding career and tireless service, including the New York Journal Lifetime Achievement Award, the Legal Aid Society Servant of Justice Award, the NOW Legal Defense and Education “Aiming High” Award and the NYU Outstanding Alumna Award.
“Sara will be leaving a legacy of true dedication, passion, and professionalism at ELC,” said Leonard A. Lauder, Chairman Emeritus. “On behalf of the company and the entire Lauder family, I would like to thank Sara for her tremendous contributions to our business over the past 20 years and wish her the very best in her well-deserved retirement.”
About The Estée Lauder Companies Inc.
The Estée Lauder Companies Inc. is one of the world’s leading manufacturers, marketers and sellers of quality skin care, makeup, fragrance, and hair care products. The Company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Lab Series, Origins, M·A·C, La Mer, Bobbi Brown, Aveda, Jo Malone London, Bumble and bumble, Darphin Paris, TOM FORD BEAUTY, Smashbox, AERIN Beauty, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, Too Faced, Dr.Jart+, and the DECIEM family of brands, including The Ordinary and NIOD.
ELC-C
ELC-L
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230425005169/en/
Contact information
Media Relations:
Jill Marvin
jimarvin@estee.com
Investor Relations:
Rainey Mancini
rmancini@estee.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
